Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

European Journal of Cancer

Volumn 49, Issue 8, 2013, Pages 1808-1814

  Seymour, Lesley K ^a   Calvert, A Hilary ^b   Lobbezoo, Marinus W ^d   Eisenhauer, Elizabeth A ^a   Giaccone, Giuseppe ^c  

^a Queen's Cancer Research Institute   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NDDO Education Foundation   (Netherlands)

Author keywords

Combination studies; Novel therapy; Phase I trials; Recommendations; Targeted therapy

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BAYESIAN LEARNING; CIRCULATING TUMOR CELL; CLASSIFIER; COOPERATION; DRUG EFFICACY; HEREDITY; HUMAN; KNOWLEDGE; MOLECULARLY TARGETED THERAPY; PATIENT COMPLIANCE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TUMOR REGRESSION;

ADVISORY COMMITTEES; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; THERAPIES, INVESTIGATIONAL;

EID: 84876683162     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.01.014     Document Type: Article

References (29)

1. J. Huang, W. Zhang, D. Bowen, J. Tam, H. Wu, and M. Fung Emerging trends in US oncological approvals: a 13-year review (1999-2011) Drug Inf J 46 3 2012 344 357
2. M. Wang, J. Zhao, and L.M. Zhang Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer J Cancer Res Clin Oncol 138 2012 2069 2077 10.1007/s00432-012-1291-2 [Epub 2012 Jul 22]
3. S.A. Aziz, L.B. Jilaveanu, and C. Zito Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma Clin Cancer Res 16 2010 6029 6039
4. T. De Raedt, Z. Walton, and L. Jessica Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors Cancer Cell 20 2011 400 413
5. G. Tortora, R. Bianco, and G. Daniele Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies Drug Resist Update 10 2007 81 100
6. H.E. Jones, L. Goddard, and J.M. Gee Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocr Relat Cancer 11 2004 793 814
7. J.C. Soria, and C. Massard From theoretical synergy to clinical supra-additive toxicity J Clin Oncol 27 2009 1359 1361
8. R.W. Humphrey, L.M. Brockway-Lunardi, and D.T. Bonk Opportunities and challenges in the development of experimental drug combinations for cancer J Natl Cancer Inst 103 2011 1 5
9. S. Kummar, H.X. Chen, and J. Wright Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements Nat Rev Drug Discovery 9 2010 843 856
10. S. Negrier, G. Gravis, and D. Perol Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial Lancet 12 2011 673 680
11. E.L. Kwak, J.W. Clark, and B. Chabner Targeted agents: the rules of combination Clin Cancer Res 13 2007 5232 5237
12. A. Clark, M. Ellis, C. Erlichman, S. Lutzker, and J. Zwiebel Development of rational drug combinations with investigational targeted agents Oncologist 15 2010 496 499
13. C.M. Booth, A.H. Calvert, G. Giaccone, M.W. Lobbezoo, L.K. Seymour, and E.A. Eisenhauer Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) EJC 44 1 2008 19 24
14. C.M. Booth, A.H. Calvert, G. Giaccone, M.W. Lobbezoo, E.A. Eisenhauer, and L.K. Seymour Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT) EJC 44 2008 125 129
15. R. Goodwin, G. Giaccone, H. Calvert, M. Lobbezoo, and E.A. Eisenhauer Targeted agents: How to select the winners in preclinical and early clinical studies? Eur J Cancer 48 2012 2170 2178
16. J.D. Hainsworth, D.R. Spigel, H.A. Burris III, D. Waterhouse, B.L. Clark, and R. Whorf Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J Clin Oncol 28 2010 2131 2136
17. S.M. Chang, J. Kuhn, and K. Lamborn Phase I/II study of Erlotinib and Temsirolimus for patients with recurrent malignant gliomas J Clin Oncol 27 2009 15s
18. M. Ronald, R.M. Bukowski, and F.F. Kabbinavar Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J Clin Oncol 25 2007 4536 4541
19. E.C. Borden, and A. Dowlati Phase I trials of targeted anticancer drugs: a need to refocus Nat Rev Drug Discovery 11 2012 889 890
20. E.E. Schadt, S.H. Friend, and D.A. Shaywitz A network view of disease and compound screening Nat Rev Drug Discovery 8 2009 286 295
21. T. Voskoglou-Nomikos, J. Pater, and L. Seymour Clinical predictive value of the in vitro cell line, human xenograft and mouse allograft pre-clinical cancer models Clin Cancer Res 9 2003 4227 4239
22. C. Le Tourneau, J.J. Lee, and L.L. Siu Dose escalation methods in Phase I cancer clinical trials J Natl Cancer Inst 101 2009 708 720
23. D.R. Parkinson, B.E. Johnson, and G.W. Sledge Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics Clin Cancer Res 18 2012 619 624
24. J.E. Dancey, K.K. Dobbin, and S. Groshen Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents Clin Cancer Res 16 6 2010 1745 1755
25. A.A. Dar, L.W. Goff, S. Majid, J. Berlin, and W. El-Rifai Aurora kinases' inhibitors-rising stars in cancer therapeutics? Mol Cancer Ther. 9 2 2010 268
26. C. Underhill, M. Toulmonde, and H. Bonnefoi A review of PARP inhibitors: from bench to bedside Ann Oncol 22 2 2010 268 279
27. J.J. Lee, N. Chen, and G. Yin Worth adapting? Revisiting the usefulness of outcome-adaptive randomization Clin Cancer Res 18 2012 4498
28. M. Pirmohamed, G.P. Aithal, E. Behr, A. Daly, and D. Roden The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions Clin Pharmacol Ther 89 2011 784 785
29. L. Wang, and R.M. Weinshilboum Pharmacogenomics: candidate gene identification, functional validation and mechanisms Hum Mol Genet 17 2008 R174 R179